EF5 to Evaluate Tumor Hypoxia in Patients With High-Grade Soft Tissue Sarcoma or Mouth Cancer
NCT ID: NCT00896961
Last Updated: 2013-01-16
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
NA
120 participants
INTERVENTIONAL
2001-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
EF5 Compared With Other Methods of Detecting Oxygen Levels in Tumor Cells of Patients With Head and Neck Cancer
NCT00049140
Fluorine F 18 EF5 Positron Emission Tomography in Assessing Hypoxia in Patients With Newly Diagnosed Stage I, Stage II, Stage III, or Stage IV Head or Neck Squamous Cell Cancer of the Oral Cavity, Oropharynx, and Larynx
NCT01020097
Open-Label Trial Of Oral PF-00299804 By Continuous Dosing In Patients With Recurrent Or Metastatic Head And Neck Squamous Cell Cancer
NCT00768664
Perifosine in Treating Patients With Metastatic or Locally Advanced Soft Tissue Sarcoma
NCT00053794
Identification of Breath Biomarkers in Head and Neck Squamous Cell Carcinoma
NCT02156180
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
I. Determine biologically-relevant hypoxia by imaging and cellular analysis of EF5 binding in patients with high-grade soft tissue sarcoma of the trunk or extremity or squamous cell carcinoma of the oral cavity.
II. Determine the spatial relationships between EF5 binding and various tumor tissue markers, pathological processes, and serum plasminogen activator inhibitor-1 in these patients.
III. Correlate EF5 binding with Eppendorf electrode measurement and patient-related factors in these patients.
IV. Determine the adjusted and unadjusted associations between clinical outcome and optimal measures of EF5 binding, patient/tumor characteristics, and biological markers in these patients.
OUTLINE:
Approximately 24-48 hours prior to surgical resection or biopsy, patients receive EF5 IV over no more than 2½ hours. Tissue samples are analyzed by immunohistochemistry for EF5 binding. Blood samples are analyzed for genetic markers and cytokines associated with hypoxia and EF5 concentration.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Observational (EF5)
Approximately 24-48 hours prior to surgical resection or biopsy, patients receive EF5 IV over no more than 2½ hours. Tissue samples are analyzed by immunohistochemistry for EF5 binding. Blood samples are analyzed for genetic markers and cytokines associated with hypoxia and EF5 concentration.
EF5
diagnostic laboratory biomarker analysis
pharmacological study
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
EF5
diagnostic laboratory biomarker analysis
pharmacological study
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Clinical imaging of mass that is likely to be STS or squamous cell carcinoma of the head and neck allowed if surgery is indicated prior to definitive diagnosis
* Planned resection and standard oncologic treatment
* No known distant metastatic disease
* ECOG 0-2
* WBC at least 2,000/mm\^3
* Platelet count at least 100,000/mm\^3
* Bilirubin less than 2.0 mg/dL
* Creatinine less than 2.0 mg/dL OR creatinine clearance at least 50 mL/min
* No significant cardiac condition that would preclude study compliance
* Weight no greater than 130 kg
* No grade III or IV peripheral neuropathy
* No other medical condition that would preclude study compliance
* Not pregnant or nursing
* Fertile patients must use effective contraception
* See Disease Characteristics
* No chemotherapy within 3 months before planned surgery
* Preoperative radiotherapy allowed for STS
* No radiotherapy within 3 months before planned surgery
* No other concurrent investigational agents
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Cancer Institute (NCI)
NIH
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Stephen Michael Hahn
Role: PRINCIPAL_INVESTIGATOR
Abramson Cancer Center at Penn Medicine
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Abramson Cancer Center of The University of Pennsylvania
Philadelphia, Pennsylvania, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
UPCC# 3300
Identifier Type: -
Identifier Source: secondary_id
CDR0000078671
Identifier Type: REGISTRY
Identifier Source: secondary_id
NCI-2012-02489
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.